Adjunctive OV329 in Adults with Drug-Resistant Focal Epilepsy

Phase 2, randomised, double-blind trial in Focal Onset Epilepsy comparing OV329 adjunctive arm with Placebo adjunctive arm (2 arms). Primary endpoints: Incidence, severity, and temporal profile of treatment-emergent adverse events, Incidence of clinically significant abnormalities in vital signs, ECGs, laboratories, and physical examinations and 1 more. Planned start Aug 2026; status: authorised.